News & Events

We are delighted to congratulate our colleagues from the Central and South Eastern European Melanoma Expert Group on the outstanding achievement of having documented more than 8,000 patients in their...

We extend our heartfelt congratulations to our Swiss colleagues for providing over 1,000 patients to our European Melanoma Registry. This remarkable achievement highlights their dedication and commitm...

We are pleased to announce that Lithuania, represented by the National Cancer Institute Vilnius, has joined our registry. As a result, our EUMelaReg now comprises 18 member countries. We warmly welcom...

Congratulations to our Steering Committee Chairman Dirk Schadendorf, Director of the Department of Dermatology at Essen University Hospital and Head of the West German Tumour Centre (WTZ), who receive...

We are pleased to inform you that another EMR real-world study “Real-World efficiency of pembrolizumab in metastatic melanoma patients following adjuvant anti-PD1 treatment” has been published in EJC...

We are delighted to announce that our multi-country real-world study “Adjuvant use of Pembrolizumab for Stage III Melanoma in a Real-World Setting in Europe” has been accepted by the journal Cancers....

We are proud to announce that our EUMelaReg board member John Haanen received the prestigious ESMO Lifetime Achievement Award at ESMO 2024, which honors outstanding lifetime achievements in oncology....

Our annual meeting took place in Barcelona in September, which was, as usual, an inspiring exchange and provided new impulses for the coming year. The event offered participants the opportunity to pre...

We are very pleased to announce that we have started our new non-interventional observational study entitled “Decision for or against anti-PD1 Treatment In Adjuvant Setting of Patients across Europe w...

A significant proportion of patients with non-resectable melanoma treated with immune checkpoint inhibitors (ICI) achieve durable remissions, but there is limited data on the optimal duration of ICI t...

We are proud to announce that after 6 years of intensive registry work, we have reached a significant milestone: Our European Melanoma Registry now includes quality approved data from more than 15,000...

A new non-interventional observational study called “Decision for or against anti-PD1 Treatment In Adjuvant Setting of Patients across Europe with Resected Stage IIB/IIC Melanoma (DECIDE II)" in colla...

Bulgaria hosted this year's two-day EUMelaReg retreat, which took place from 25-26 January in Sofia. The two-day meeting brought together more than 40 leading oncologists and specialists from 17 Europ...